HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
Home » News » Lunit to Present Real-World Data of First AI in Breast Cancer Research

Lunit to Present Real-World Data of First AI in Breast Cancer Research

Lunit has extended its artificial intelligence (AI) efforts into the field of breast cancer, releasing real-world data (RWD) demonstrating promising results. Researchers used the AI to identify cancer from mammograms, beating a team of two radiologists in diagnostic accuracy. The data comes from a pool of nearly 56,000 patient mammograms. The research will be presented in several forms at the upcoming RSNA Annual Meeting.

According to PR Newswire, “Interpreting mammograms is an inherently difficult task. Once suspicious lesions are found through mammograms, women are recalled to the clinic for further tests and biopsies. While recalls are aimed to increase the detection of cancer, only fewer than 1 in 10 women called back are diagnosed with breast cancer. These false-positive mammograms can cause patient anxiety and physical discomfort, as well as cost significant time and money due to extra tests, potentially doing more harm than good. To tackle this problem, most European countries have adopted a system of double reading in which two radiologists decide whether the patient should be recalled or not.”

To read more, click here.

(Source: PR Newswire, November 28th, 2022)

You might be interested in:

  1. IQVIA Partners with Janssen R & D on COVID-19 Vaccine Trial, RWD To Be Utilized in Phase 3 Trial
  2. New Report Discusses RWD and RWE in Regulatory Approval Process, Notes 82% of Submissions Using RWE Gain Orphan Drug Designation
  3. HTA Submissions and Single-Arm Trials: An ISPOR EUROPE Panel Presentation
  4. Ciitizen Real-World Data Platform Used in Regulatory Filing for Precision Medicine Regulatory Filing

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • SQL Developer
  • Senior Research Consultant - Modelling and Meta Analysis
  • Research Consultant - Evidence Synthesis & Economic Modelling
  • Associate Director – Modelling & Meta-Analysis
  • Associate Director, Real World Evidence
 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists